In vitro methods in the prediction of kinetics of drugs: Focus on drug metabolism

Alternatives to Laboratory Animals

Volumn 32, Issue 4, 2004, Pages 425-430

  Raunio, Hannu ^a   Taavitsainen, Päivi ^b   Honkakoski, Paavo ^a   Juvonen, Risto ^a   Pelkonen, Olavi ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

CYP; Cytochrome P450; Drug metabolism

Indexed keywords

CYTOCHROME P450;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; COMPUTER MODEL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INTESTINE ABSORPTION; PASSIVE TRANSPORT; PRIORITY JOURNAL;

ANIMALIA;

EID: 12344308043     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290403200415     Document Type: Conference Paper

References (14)

1. Lipinski, C.A. (2003). Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discovery Today 8, 12-16.
2. Li, A.P. (2001). Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today 6, 357-366.
3. Pelkonen, O., Boobis, A.R. & Gundert-Remy, U. (2001). In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. European Journal of Clinical Pharmacology 57, 621-629.
4. Burton, P.S., Goodwin, J.T., Vidmar, T.J. & Amore, B.M. (2002). Predicting drug absorption: how nature made it a difficult problem. Journal of Pharmacology and Experimental Research 303, 889-895.
5. Pelkonen, O., Mäenpää, J., Taavitsainen, P., Rautio, A. & Raunio, H. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28, 1203-1253.
6. Houston, J.B. & Galetin, A. (2003). Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metabolism Reviews 35, 393-415.
7. Yuan, R., Parmelee, T., Balian, J.D., Uppoor, R.S., Ajayi, F., Burnett, A., Lesko, L.J. & Marroum, P. (1999). In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clinical Pharmacology and Therapeutics 66, 9-15.
8. Honkakoski, P. (2003). Nuclear receptors CAR and PXR in metabolism and elimination of drugs. Current Pharmacogenomics 1, 75-85.
9. Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P. & Pelkonen, O. (2002). In silico prediction of ADME and pharmacokinetics: report of an expert meeting organised by COST B15. European Journal of Pharmaceutical Sciences 17, 183-193.
10. Butina, D., Segall, M.D. & Frankcombe, K. (2002). Predicting ADME properties in silica: methods and models. Drug Discovery Today 7, Suppl. 11, S83-S88.
11. Beresford, A.P., Selick, H.E. & Tarbit, M.H. (2002). The emerging importance of predicitive ADME simulation in drug discovery. Drug Discovery Today 7, 109-116.
12. Yu, H. & Adedoyin, A. (2003). ADME-Tox in drug discovery: integration of experimented and computational technologies. Drug Discovery Today 8, 852-861.
13. van de Waterbeemd, H. & Gifford, E. (2003). ADMET in silico modelling: towards prediction paradise? Nature Reviews in Drug Discovery 2, 192-204.
14. Greene, N. (2002). Computer systems for the prediction of toxicity: an update. Advanced Drug Delivery Reviews 54, 417-431.